ARIDIS PHARMACEUTICALS INC (ARDS)
US0403341045 - Common Stock
Overall ARDS gets a fundamental rating of 2 out of 10. We evaluated ARDS against 588 industry peers in the Biotechnology industry. ARDS may be in some trouble as it scores bad on both profitability and health. ARDS is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year ARDS has reported negative net income.
In the past year ARDS has reported a negative cash flow from operations.
In the past 5 years ARDS always reported negative net income.
ARDS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The profitability ratios for ARDS are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ARDS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARDS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARDS has been increased compared to 1 year ago.
Compared to 5 years ago, ARDS has more shares outstanding
The debt/assets ratio for ARDS has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -43.31, we must say that ARDS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -43.31, ARDS is doing worse than 96.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -43.31 |
ROIC/WACCN/A
WACC8.46%
2.3 Liquidity
A Current Ratio of 0.19 indicates that ARDS may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.19, ARDS is doing worse than 99.15% of the companies in the same industry.
A Quick Ratio of 0.19 indicates that ARDS may have some problems paying its short term obligations.
With a Quick ratio value of 0.19, ARDS is not doing good in the industry: 99.15% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.19 | ||
| Quick Ratio | 0.19 |
3. Growth
3.1 Past
ARDS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.11%, which is quite impressive.
Looking at the last year, ARDS shows a quite strong growth in Revenue. The Revenue has grown by 9.70% in the last year.
Measured over the past years, ARDS shows a very strong growth in Revenue. The Revenue has been growing by 29.16% on average per year.
EPS 1Y (TTM)53.11%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q48.92%
Revenue 1Y (TTM)9.7%
Revenue growth 3Y44.71%
Revenue growth 5Y29.16%
Revenue growth Q2Q-8.85%
3.2 Future
ARDS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.36% yearly.
ARDS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 145.96% yearly.
EPS Next Y71.9%
EPS Next 2Y46.13%
EPS Next 3Y40.36%
EPS Next 5YN/A
Revenue Next Year1609.12%
Revenue Next 2Y334.44%
Revenue Next 3Y225.86%
Revenue Next 5Y145.96%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ARDS. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 1.17, which indicates a rather cheap valuation of ARDS.
ARDS's Price/Forward Earnings ratio is rather cheap when compared to the industry. ARDS is cheaper than 99.66% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ARDS to the average of the S&P500 Index (21.27), we can say ARDS is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.17 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ARDS's earnings are expected to grow with 40.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.13%
EPS Next 3Y40.36%
5. Dividend
5.1 Amount
No dividends for ARDS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARIDIS PHARMACEUTICALS INC
NASDAQ:ARDS (7/18/2023, 7:14:23 PM)
After market: 0.2619 -0.05 (-15.54%)0.3101
+0.05 (+17.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.23M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.17 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.19 | ||
| Quick Ratio | 0.19 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)53.11%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y71.9%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)9.7%
Revenue growth 3Y44.71%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y